Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRYLBW)

Drug Name

NTO-1151 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cervical cancer	2C77.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ribonuclease (RNase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranpirnase	DMM15RI	Lung cancer	2C25.0	Phase 2	[3]
MazF gene therapy	DMSZ8HT	Human immunodeficiency virus-1 infection	1C62	Phase 1	[4]
AS-1406	DMRYQBE	Solid tumour/cancer	2A00-2F9Z	Terminated	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of Nanotherapeutics.
2	Clinical pipeline report, company report or official report of Nanotherapeutics.
3	Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27.
4	Clinical pipeline report, company report or official report of Takara Bio.
5	WO patent application no. 2005,0657,17, Liquid formulations of antibody conjugates.